ReviewMedComm2026
Progress in Natural Products Target Discovery Technology.
Review in MedComm, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Natural products, owing to their unique biological activities, possess the ability to interact with specific target proteins or regulatory networks, representing a valuable source of innovative drug candidates. However, target identification remains a major bottleneck in natural product-based drug discovery, largely because of the chemical complexity of natural products and the heterogeneity of biological systems. To address these challenges, various complementary strategies have been developed, including experimental strategies such as chemical proteomics, and computational methods such as artificial intelligence-driven methods. Nevertheless, reliably advancing a candidate protein hit to a therapeutically relevant and physiologically validated target remains a critical challenge. Focusing on technologies for natural product target discovery, this review systematically summarizes the principles, methodologies, and practical applications of current approaches. Through representative case studies, we further propose a reusable integrated experimental-computational workflow and illustrates how key targets and their modes of action can be identified in real-world research scenarios. In addition, we discuss common technical and conceptual bottlenecks encountered during target discovery and proposes potential countermeasures. The review provides an actionable reference framework for natural product target identification, with the goal of reducing false-positive findings and fragmented evidence, thereby improving the robustness of mechanism-oriented studies and facilitating subsequent translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.